ELIAS Animal Health announces the latest additions to its team
The positions of sales, marketing & business development leader as well as 2 scientific advisory board members were filled by noteworthy candidates to help further advance the company's adoptive cell therapies for canine cancer.
ELIAS Animal Health—a clinical stage development company accelerating novel treatments for veterinary oncology—has appointed Caroline Garrison as sales, marketing & business development leader, and Zachary Wright, DVM, DACVIM (Oncology) and Amanda Foskett, DVM, DACVIM (Oncology) to its scientific advisory board.
"Caroline's experience in life sciences and proven ability to propel organizations forward will be critical as ELIAS looks to expand its immunotherapy pipeline," said Tammie Wahaus, CEO of ELIAS Animal Health, in a company release.
"I am also pleased to add two veterinary oncologists to our advisory board. Drs. Wright and Foskett bring an invaluable perspective on the advancement of animal cancer treatments," she added.
Garrison has an extensive background in the animal health industry and the bioprocessing industry with previous positions at CEVA Animal Health (then known as Sanofi Animal Health) and Bayer Animal Health. Her responsibilities majorly consisted of global roles in the commercial functions of sales, marketing, and business development including the complete licensing of technologies. As a French native, she received degrees both in France and the United States.
Wright is the medical director at Animal Diagnostics Clinic at VCA Hospitals in Dallas, Texas. He received his veterinary medical degree from Texas A&M University and completed a 1-year rotating small animal internship in medicine and surgery at VCA West Los Angeles Animal Hospital in Los Angeles, California. He completed his residency in small animal oncology at Texas A&M University and in 2008 became a Diplomate of the American College of Veterinary Internal Medicine-Oncology. He has published scientific articles and book chapters in small animal oncology and has held several roles within the American College of Veterinary Medicine, including positions on the board of regents. Wright regularly engages in clinical trials at VCA Animal Diagnostic Clinic which includes the ECI-OSA-04 canine osteosarcoma clinical trial.
Foskett is a veterinary oncologist at Friendship Hospital for Animals in Washington, D.C. She obtained her veterinary medical degree from the University of Florida, and after veterinary school, completed a 1-year rotating internship in medicine and surgery at Friendship Hospital for Animals, followed by a 3-year medical oncology residency program with The Oncology Service. Foskett's areas of interest are comparative oncology and small animal internal medicine. She regularly partakes in clinical trials discovering new treatments for canine and feline cancer, including the ELIAS ECI-OSA-04 trial.
ELIAS Animal Health announces addition of sales, marketing & business development leader and expansion of scientific advisory board. News release. ELIAS Animal Health. November 23, 2021. Accessed November 23, 2021. https://www.prnewswire.com/news-releases/elias-animal-health-announces-addition-of-sales-marketing--business-development-leader-and-expansion-of-scientific-advisory-board-301430378.html